well-positioned to offer testing for these infectious diseases to a high-risk population. They were among the first venues to offer HIV testing and are more likely to offer HIV, STI, and HCV testing than other drug treatment programs.
1 Private for-profit opioid treatment programs are increasingly widespread and such programs offer on-site HIV testing less often than nonprofit and public programs. Results | The number of US opioid treatment programs increased from 849 in 2000 to 1175 in 2011. The percentage of programs operating as for-profit businesses increased from 43% to 54%, nonprofits decreased from 43% to 36%, and public programs decreased from 14% to 10%. From 2000 to 2011, the absolute number of programs offering testing for HIV, STIs, and HCV increased but the percentage offering on-site testing for HIV declined by 18% (95% CI, 13%-23%; P < .001) and for STIs by 13% (95% CI, 7%-18%; P < .001). There was no significant change for HCV testing (P = .63; Figure 1 ).
More than 75% of public programs offered on-site testing for each infection, with no significant change over time. Offering on-site HIV testing declined by 20% (95% CI, 10%-29%; P < .001) among for-profit programs and by 11% (95% CI, 6%-17%; P < .001) among nonprofit programs (Figure 2) . Offering on-site STI testing declined by 23% (95% CI, 16%-30%; P < .001) in for-profit programs. Offering HCV testing declined by 13% (95% CI, 3%-22%; P = .002) in for-profit programs and increased by 14% (95% CI, 4%-25%; P < .001) in nonprofit programs.
Conclusion | The proportion of US opioid treatment programs offering on-site testing for HIV and STIs declined substantially between 2000 and 2011, despite guidelines recommending routine opt-out HIV testing in all health care settings, including substance abuse treatment facilities. Declines were most pronounced in for-profit programs, suggesting that persons enrolled in these programs may be at increased risk for delayed diagnosis and continued transmission of HIV, STIs, and HCV.
This study had limitations. Referral-based testing was not recorded; however, referral-based services often do not translate into patient use. 6 Testing for STIs may be limited 
